• 대학교육
• /
• s.109
• /
• pp.22-29
• /
• 2001

• 월간산업보건
• /
• s.91
• /
• pp.17-22
• /
• 1995

• Journal of Korea Fishing Vessel Association
• /
• v.51
• /
• pp.12-22
• /
• 1992

• 월간산업보건
• /
• s.131
• /
• pp.22-24
• /
• 1999

• Korean Architects
• /
• no.10 s.116
• /
• pp.19-22
• /
• 1978

• 사료
• /
• s.41
• /
• pp.22-27
• /
• 2009

• Journal of Pharmacopuncture
• /
• v.22 no.3
• /
• pp.122-130
• /
• 2019

Objectives: The medicinal plants are believed to enhance the natural resistance of the body to infections. Some of the main constituents of the plant and derived materials such as, proteins, lectins and polysaccharides have anti-inflammatory effects. Portulaca oleracea (P. oleracea) were used traditionally for dietary, food additive, spice and various medicinal purposes. This review article is focus on the anti-asthmatic effects of P. oleracea and its constituents. Methods: Various databases, such as the PubMed, Scopus, and Google Scholar, were searched the keywords including "Portulaca oleracea", "Quercetin", "Anti-inflammatory", "Antioxidant", "Cytokines", "Smooth muscle ", and " Relaxant effects " until the end of Jul 2018. Results: P. oleracea extracts and its constituents increased $IFN-{\gamma}$, IL-2, $IFN{\gamma}/IL-4$ and IL- 10/IL-4 ratio, but decreased secretion of $TNF-{\alpha}$, IL-4 and chemokines in both in vitro and in vivo studies. P. oleracea extracts and quercetin also signifcantly decreased production of NO, stimulated ${\beta}$-adrenoceptor and/or blocking muscarinic receptors in tracheal smooth muscles. Conclusion: P. oleracea extracts and quercetin showed relatively potent anti-asthmatic effects due to decreased production of NO, inflammatory cytokines and chemokines, reduced oxidant while enhanced antioxidant markers, and also showed potent relaxant effects on tracheal smooth muscles via stimulatory on ${\beta}$-adrenoceptor or/and blocking muscarinic receptors.

• International Journal of Computer Science & Network Security
• /
• v.22 no.1
• /
• pp.61-68
• /
• 2022

The present study was based on developing an AI based model to facilitate the academic registration needs of blind students. The model was developed to enable blind students to submit academic service requests and tasks with ease. The findings from previous studies formed the basis of the study where functionality gaps from the literary research identified by blind students were utilized when the system was devised. Primary simulation data were composed based on several thousand cases. As such, the current study develops a model based on archival insight. Given that the model is theoretical, it was partially applied to help determine how efficient the associated AI tools are and determine how effective they are in real-world settings by incorporating them into the portal that institutions currently use. In this paper, we argue that voice-activated personal assistant (VAPA), text mining, bag of words, and case-based reasoning (CBR) perform better together, compared with other classifiers for analyzing and classifying the text in academic request submission through the VAPA.

• Journal of Periodontal and Implant Science
• /
• v.33 no.4
• /
• pp.739-745
• /
• 2003

Interleukine-1(IL-1)은 여러 가지 기능을 가진 싸이토카인으로써 미생물에 대한 면역반응을 일으킨다. IL-1의 유전자 다형성과 치주질환과의 관련성에 대한 많은 연구가 있어왔지만, 대부분이 백인을 대상으로 한 연구였다. 이후 중국인과 일본인을 대상으로 한 연구에서 IL-1의 유전자 다형성의 분포가 인종간에 차이를 보인다는 점이 발견되었다. 이번 연구에서는 치주적으로 건강한 한국인에서 IL-1${\beta}$-511, IL-1${\beta}$+3954, IL-1RN에 대한 유전자형의 분포를 조사하고자 하였다. 서울대학교 치과병원에 근무하는 치과의사, 치과위생사, 간호조무사 및 서울대학교 치과대학 4학년 학생 중 치주낭 깊이와 부착소실이 4mm 이하인 치주적으로 건강한 한국인 65명을 대상으로 하였다. IL-1${\beta}$-511, IL-1${\beta}$+3954, IL-1RN의 유전자 다형성은 분리한 DNA에 각 대립유전자에 특이성을 지닌 primer를 넣고 PCR(Polymerase Chain Reaction)법을 이용하여 증폭시킨후 전기영동법을 이용하여 각 대립유전자의 존재를 확인함으로써 결정하였다. IL-1${\beta}$-511 대립유전자 11, 대립유전자 12, 대립유전자 22의 유전자형에 대하여 각각 23.1%, 49.2%, 26.2%의 분포를 보였다. IL-1${\beta}$+3954의 유전자 다형성은 대립유전자 11, 대립유전자 12의 유전자형에 대하여 각각 89.2%, 10.8%의 분포를 보였으며, 대립유전자 22의 유전자형을 갖는 사람은 한명도 발견되지 않았다. IL-1RN의 유전자형은 5가지의 대립유전자 중에서 1, 대립유전자 2, 대립유전자 4만일 발견되었으며, 대립유전자 11, 대립유전자 12, 대립유전자 14의 유전자형이 86.2%, 12.3%, 1.5%로 분포하였다. 이를 바탕으로 각 대립유전자의 발생빈도 계산한 결과 IL-1${\beta}$-511에서는 대립유전자 1과 2의 비율이 거의 유사하였으나 (47.7%, 52.3%), IL-1${\beta}$+3954, IL-1RN에서는 대립유전자 1이 90%이상 발견되었으며, 또한 대립유전자 1외의 다른 대립유전자가 발견된 경우, 모두 이형접합체였다. 이 연구는 IL-1${\beta}$-511, IL-1${\beta}$+3954, IL-1RN에 대한 유전자형의 분포를 조사한 것으로 한국인에서 이들 유전자의 유전자형의 분포는 백인에서의 분포와 차이를 보이고 있었다. 이후 치주질환자의 유전자형 분포와의 비교로 치주질환과 IL-1${\beta}$-511, IL-1${\beta}$+3954, IL-1RN의 유전자다형성과의 관련성에 관한 추가적인 연구가 필요할 것으로 여겨진다.

• IMMUNE NETWORK
• /
• v.22 no.6
• /
• pp.51.1-51.20
• /
• 2022

Trypanosoma cruzi, the etiological agent of Chagas disease, is an intracellular protozoan parasite, which is now present in most industrialized countries. About 40% of T. cruzi infected individuals will develop severe, incurable cardiovascular, gastrointestinal, or neurological disorders. The molecular mechanisms by which T. cruzi induces cardiopathogenesis remain to be determined. Previous studies showed that increased IL-6 expression in T. cruzi patients was associated with disease severity. IL-6 signaling was suggested to induce pro-inflammatory and pro-fibrotic responses, however, the role of this pathway during early infection remains to be elucidated. We reported that T. cruzi can dysregulate the expression of host PIWI-interacting RNAs (piRNAs) during early infection. Here, we aim to evaluate the dysregulation of IL-6 signaling and the piRNAs computationally predicted to target IL-6 molecules during early T. cruzi infection of primary human cardiac fibroblasts (PHCF). Using in silico analysis, we predict that piR_004506, piR_001356, and piR_017716 target IL6 and SOCS3 genes, respectively. We validated the piRNAs and target gene expression in T. cruzi challenged PHCF. Secreted IL-6, soluble gp-130, and sIL-6R in condition media were measured using a cytokine array and western blot analysis was used to measure pathway activation. We created a network of piRNAs, target genes, and genes within one degree of biological interaction. Our analysis revealed an inverse relationship between piRNA expression and the target transcripts during early infection, denoting the IL-6 pathway targeting piRNAs can be developed as potential therapeutics to mitigate T. cruzi cardiomyopathies.